How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Want to cut your energy bills? Here’s how five experts are doing it 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
VANCOUVER, British Columbia, March 08, 2016 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, will report its year end 2015 financial results and provide a general business update on Monday, March 14, 2016 after U.S. financial markets close. Aquinox will host a conference call and live audio webcast on Monday, March 14, 2016 at 4:30 PM (ET) / 1:30 PM (PT).
Conference Call and Webcast Details:
Date: Monday, March 14th, 2016
Time: 4:30 PM (ET) / 1:30 PM (PT)
Toll-free: (866) 357-7878
International: (315) 625-3088
Conference ID: 59998679
Webcast URL: http://edge.media-server.com/m/p/9brvbrt5
The live audio webcast may be accessed through the "Events & Presentations" page in the "Investor Relations" section of the company's website at www.aqxpharma.com.
The archived conference call will also be available on Aquinox’s website approximately two hours after the event and will be available for replay for at least 30 days after the event.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. With a successful Phase 2 clinical trial completed in 2015, Aquinox plans to initiate a Phase 3 trial in 2016 with AQX-1125 for treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.
For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Senior Manager, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.629.9223 Ext. 109
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
